Inflammatory bowel disease
Conditions
Interventions
control group:conventional therapy
Sponsors
Department of Gastroenteroly, the Second Hosptial of Anhui Medical Univerisity
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for patients with ulcerative colitis: (1) Patients with recurrent ulcerative colitis in the active period were diagnosed; (2) Older than 18-75, regardless of gender; (3) The patient has received a stable combined dose (aminosalicylic acid preparation) for at least 4 weeks; (4) No history of antibiotics, probiotics or probiotics in at least one month; (5) No history of intestinal preparation before colonoscopy for at least one month; (6) Voluntarily participate in this clinical trial and sign the informed consent; (7) The patient is willing to accept later follow-up and other protocol requirements. 2. Inclusion criteria for crohn patients: (1) Diagnosis of active relapsing Crohn disease; (2) Older than 18-75, regardless of gender; (3) The patient has received a stable combined dose (aminosalicylic acid preparation) for at least 4 weeks; (4) No history of antibiotics, probiotics or probiotics in at least one month.
Exclusion criteria
Exclusion criteria: 1. Women who have a pregnancy plan during pregnancy or the trial period; 2. Patients have any doubts about the technology or have a history of other risks; 3. The patient is in the terminal stage of the disease or may die in the study; 4. The patient had a history of antibiotic use three months before the transplant or participated in other clinical trials; 5. Have participated in any other bacterial community treatment before inclusion; 6. Hepatitis b, tuberculosis, syphilis and HIV antibody positive or any infectious disease or infectious disease acute phase; 7. Cardiac function III level and above, more than twice the upper limit of normal transaminase eleations, renal insufficiency glomerular filtration rate (GFR below 60 ml/min). 8. Febrile temperature above 38 degrees C or clinically significant active infection that can affect this study; 9. Severe anemia (hemoglobin < 60g/L), granulocytopenia (absolute value of neutrophils < 1.5 x 10^9/L), and prolonged PT for more than 1.5 seconds; 10. Significant cardiovascular and cerebrovascular abnormalities (such as tachycardia or uncontrolled atrial fibrillation, acute coronary syndrome, stroke or recurrent TIA attacks); History of arrhythmia (polygenic preventricular contractile, tri, tri, congenital long QT syndrome) or heart disease that increases the risk of ventricular arrhythmia as determined by the investigator; 11. Conditions identified by the investigator during the trial that may affect the subject's compliance and/or completion of trial-related procedures, or clinical contraindications related to the pre-trial; 12. The patients underwent abdominal viscera surgery three months before the fecal bacteria transplantation, and the patients were less than 6 weeks after the main viscera surgery, and the surgical wound healing was poor. 13. Patients with gastrointestinal obstructive diseases, tumors, and liver and kidney dysfunction; 14. Pregnant or nursing women or women with pregnancy intention; 15. Suspected or confirmed drug abusers, with a history of immunodeficiency (HIV antibody positive or receiving immunosuppressive therapy, etc.); 16. A major active infection is known, or a major disturbance of blood, kidney, metabolism, gastrointestinal or endocrine function is determined by the investigator 17. Staff of the research centre;The partner or first-degree relative of the researcher; 18. Other conditions considered inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy (the primary endpoint was clinical and mucosal remission); | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal flora;adverse reactions; | — |
Countries
China
Contacts
Public ContactFang haiming
The Second Hosptial of Anhui Medical Univerisity
Outcome results
None listed